Molecular Partners AG

NASDAQ:MOLN

Biotechnology

Healthcare
$2.86 +0.77%

+$0.03 today

Market cap
$109.64M
Beta
0.71
P/E (TTM)
-2.0
EPS (TTM)
-$1.55
52W Low $3.41High $5.36

Volume 0.00M

Average 0.00M

MOLN Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Molecular Partners AGNASDAQ: MOLN

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin not reported for Q1 FY2026

Context

  • Operating margin widened in 0 of the last 2 fiscal years.
  • FY2024 was the lowest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2024
-1231.7%
Year-over-year change
-363.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How MOLN compares with its peers on the latest reported figures

MOLN Competitors Peer median
Operating Margin for MOLN and competitors
Company Period LTM level YoY 3-year change
ALECAlector, Inc.LTM Mar 2026-741.3% -576.1 pp-589.7 pp
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026-1093.0% +3181.5 pp—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-3669.4% —-2848.9 pp
CRDFCardiff Oncology, Inc.LTM Mar 2026-9033.9% -173.4 pp+2081.0 pp
MOLNMolecular Partners AGFY2025— ——
PEPGPepGen Inc.FY2025— ——
NKTXNkarta, Inc.FY2025— ——
CRBPCorbus Pharmaceuticals Holdings, Inc.FY2025— ——
ELTXElicio Therapeutics, Inc.FY2025— ——
Peer median (excluding MOLN) -2381.2%-173.4 pp-589.7 pp

Competitors are the stored peer set for MOLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.33M189.56M7.04M4.97M0
Cost of Revenue55.72M50.75M47.84M47.5M2.58M
Gross Profit(46.39M)138.81M(40.81M)(42.53M)(2.58M)
Gross Margin-497.2%73.2%-579.8%-855.8%—
Research & Development55.72M50.75M48.78M48.6M40.19M
Selling, General & Admin16.91M21.82M19M17.16M14.87M
Operating Expenses72.75M72.94M20.3M18.68M50.89M
Depreciation & Amortization2.57M2.39M2.42M2.37M2.14M
EBITDA(60.66M)119M(59.52M)(51.65M)(59.49M)
EBITDA Margin-650.2%62.8%-845.6%-1039.2%—
Operating Income(63.42M)116.61M(61.11M)(61.22M)(58.12M)
Operating Margin-679.7%61.5%-868.3%-1231.7%—
Interest Income108.28K1.2M4.28M3.38M1.52M
Interest Expense608.14K648.12K49K25K18K
Other Income / Expenses(365K)1.24M(876K)7.18M(3.53M)
Income Before Tax(63.78M)117.85M(61.98M)(54.04M)(61.65M)
Pre-Tax Margin-683.6%62.2%-880.7%-1087.3%—
Income Tax Expense2K002K2K
Net Income(63.79M)117.85M(61.98M)(54.04M)(61.65M)
Net Margin-683.7%62.2%-880.7%-1087.4%—
EPS (Basic)(2.06)3.63(1.89)(1.59)(1.65)
EPS (Diluted)(2.06)3.54(1.89)(1.59)(1.65)
Weighted Avg Shares31.01M32.47M32.77M34.03M37.27M
Weighted Avg Shares (Diluted)31.01M33.27M32.77M34.03M37.27M

Molecular Partners AG

NASDAQ:MOLN

Intrinsic Alpha fair value

Locked

Current Price

$2.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.